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Abstract 
Background: Little is known about clinical associations between glucose fluctuations including hypoglycemia, heart 
rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute phase of acute 
coronary syndrome (ACS). This pilot study aimed to evaluate the short-term effects of glucose fluctuations on HRV 
and SNS activity in type 2 diabetes mellitus (T2DM) patients with recent ACS. We also examined the effect of sup-
pressing glucose fluctuations with miglitol on these variables.
Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group comparative 
study included 39 T2DM patients with recent ACS, who were randomly assigned to either a miglitol group (n = 19) 
or a control group (n = 20). After initial 24-h Holter electrocardiogram (ECG) (Day 1), miglitol was commenced and 
another 24-h Holter ECG (Day 2) was recorded. In addition, continuous glucose monitoring (CGM) was performed 
throughout the Holter ECG.
Results: Although frequent episodes of subclinical hypoglycemia (≤4.44 mmo/L) during CGM were observed on Day 
1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were 
decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical 
hypoglycemia to 7.7% in the miglitol group on Day 2. Holter ECG showed that the mean and maximum heart rate and 
mean LF/HF were increased on Day 2 in the control group, and these increases were attenuated by miglitol. When 
divided 24-h time periods into day-time (0700–1800 h), night-time (1800–0000 h), and bed-time (0000–0700 h), we 
found increased SNS activity during day-time, increased maximum heart rate during night-time, and glucose fluctua-
tions during bed-time, which were attenuated by miglitol treatment.
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Introduction
It is well established that hyperglycemia on admission to 
hospital is associated with increased mortality in patients 
with acute myocardial infarction (AMI) [1, 2]. Recent 
studies have shown that hypoglycemia is also associated 
with increased short- and long-term mortality in AMI 
patients [3–5]. Lee et al. [6] compared the prognostic sig-
nificance of hypoglycemia and hyperglycemia in 34,943 
AMI patients with or without type 2 diabetes mellitus 
(T2DM) from Korean registries. They found that admis-
sion hypoglycemia in patients with poorly controlled 
T2DM was associated with a markedly decreased 30-day 
survival rate. Nevertheless, HbA1c level was not associ-
ated with the risk of 30-day mortality.
Although the mechanism by which hypoglycemia leads 
to increased mortality is not clear, an abnormal QT pro-
longation during severe hypoglycemia may be associated 
with increased 30-day mortality [7]. In experimentally-
induced hypoglycemia, abnormal QT prolongation, sinus 
bradycardia, and ventricular arrhythmias occurred that 
were potentially fatal [8, 9]. A clinical study has described 
bradycardia during severe hypoglycemia in both diabetic 
and non-diabetic patients, which may reflect imbalance 
of the sympathetic nervous system (SNS) [7, 8]. However, 
associations between hypoglycemia, heart rate variability 
(HRV), and the activity of the SNS have not been studied 
in patients with AMI/acute coronary syndrome (ACS).
Alpha-glucosidase inhibitors (αGIs) are a class of oral 
anti-diabetic drugs that act by inhibiting the hydrolysis 
of complex carbohydrates into glucose. Although they 
lower the degree of postprandial hyperglycemia, they also 
reduce the degree of hypoglycemia, probably by dimin-
ishing postprandial hyperinsulinemia [10]. Therefore, we 
hypothesized that αGI drugs stabilize glucose fluctua-
tions, and thereby decrease the number of hypoglycemic 
episodes, in consequence lessening variation(s) in heart 
rate (HR) and/or imbalance of the SNS.
In this multicenter randomized controlled trial, we 
evaluated the effects of glucose fluctuations on HRV and 
autonomic nervous system activity in T2DM patients 
with ACS. We also investigated the effects of the αGI 
miglitol on glucose fluctuations and the other variables.
Methods
Study design
The effect of miglitol on glucose metabolism in acute cor-
onary syndrome (MACS) study is a multicenter prospec-
tive, randomized, open-label, blinded endpoint (PROBE) 
pilot study. The protocol was approved by the local Ethics 
Committees and carried out in accordance with the prin-
ciples of the Declaration of Helsinki. All subjects gave 
written informed consent. This trial has been registered 
in the University Hospital Medical Information Network 
Clinical Trials Registry (UMIN000005874).
Patients recruitment
A total of 39 T2DM patients with recent ACS were 
recruited at five sites in Japan after obtaining consent, 
and were randomly allocated to two groups with (miglitol 
group) or without (control group) miglitol per os, 50 mg 
three times daily. Inclusion criteria were as follows: (1) 
ACS for <7  days from onset; (2) fasting plasma glucose 
≥6.99  mmol/L or plasm glucose ≥11.10  mmol/L either 
postprandially or in two-hourly measurements during 
a 75  g oral glucose tolerance test (OGTT); (3) HbA1c 
<9.4% (79.2  mmol/mol); (4) men or women aged ≥20 
and <80  years; and (5) written informed consent. ACS 
was diagnosed as: (1) chest pain within 24-h of admission 
that lasted for >30 min. and was not relieved by sublin-
gual nitroglycerin; (2) ST-segment elevation and/or an 
abnormal Q-wave on electrocardiogram (ECG); and (3) 
elevated serum creatine kinase. Exclusion criteria were 
as follows: (1) type 1 diabetes mellitus or diabetes treated 
with insulin or α-GI medication; (2) severe liver disease, 
including carrier status of hepatitis B or C; (3) severe 
renal disease, including serum creatinine ≥176.8 µmol/L; 
(4) a history of gastrointestinal surgery; (5) a history of 
drug allergy; (7) pregnancy or possible pregnancy.
All patients received coronary angiography on admis-
sion and then underwent percutaneous coronary inter-
vention (PCI) using coronary stents. Patients were 
routinely treated with heparin, isosorbide dinitrate, clopi-
dogrel, aspirin, a statin, and an angiotensin-converting 
enzyme inhibitor or angiotensin II receptor blocker. All 
the patients were managed in accordance with Japanese 
Conclusions: In T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associ-
ated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological 
relationships may be a residual therapeutic target in such patients.
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guidelines for rehabilitation in patients with cardiovas-
cular disease [11]. After hemodynamic and general con-
ditions had been stabilized within 7 days of the onset of 
ACS, all patients gave informed consent to participate 
in the trial. A 2-h OGTT was performed in patients who 
had no previous diagnosis of diabetes and/or HbA1c 
<6.5% (47.5 mmol/mol).
Randomization and study intervention
Consent was obtained 2–7 days after PCI due to ACS at 
each local site, and patients were registered at the admin-
istration office of the MACS study (Department of Cardi-
ovascular Medicine, Saga University). Thereafter, patients 
were randomly assigned to the miglitol group or the con-
trol group (1:1) using a non-biased table of random num-
bers. The CGM test was initiated within the next 4 days. 
During 72-h continuous glucose monitoring (CGM) 
(Fig.  1), background medication was continued and no 
new treatment was started, in principle. If patients took 
oral antidiabetic agents and/or β-blockers, their doses 
were not changed during the study. In the miglitol group, 
treatment was initiated after an initial 48-h of CGM 
examination.
Study outcomes
The study was a post hoc exploratory analysis of the 
MACS pilot study. We evaluated short-term effects of 
glucose fluctuations on HRV and SNS activity in T2DM 
patients after recent onset of ACS. In addition, we stud-
ied the effects of miglitol on the variables.
Monitoring of continuous blood glucose and heart rate 
variability
In all participants, simultaneous monitoring of glu-
cose and Holter ECG was performed. Within 4-day of 
informed consent, patients underwent CGM using the 
CGMS (Medtronic iPro2) [12], and Holter ECG monitor-
ing was introduced 24-h after the start of CGM. CGM 
and Holter ECG were recorded during the next 48-h 
in parallel by synchronizing the timing of the devices. 
Both were recorded without pharmacological treatment 
during the first 24-h (Day 1), and then continued with 
or without miglitol per os 50  mg three times daily dur-
ing the second 24-h (Day 2) (Fig. 1). Blood glucose levels 
were calibrated by simultaneous finger-stick tests at least 
four times daily. A standard hospital diet, which con-
tained ~25 kcal/kg/day × ideal body weight (15% protein, 
23–25% fat and 60–62% glucose), was provided at around 
0800 h (8 a.m.), 1200 h (noon), and 1800 h (6 p.m.).
Intra-day glycemic variability was expressed as the mean 
amplitude of glycemic excursions (MAGE), which was cal-
culated according to Service et  al. [13] by measuring the 
arithmetic mean of differences between the consecutive 
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Fig. 1 Study outline. ACS acute coronary syndrome
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deviation around the mean glucose level. Measurements of 
the peak-to-nadir or nadir-to-peak directions were deter-
mined by the first qualifying excursion. Hypoglycemia 
was defined as glucose ≤4.44  mmol/L in the CGM sys-
tem [14]. Hermanns et al. [14] reported that if the point of 
care (POC) measurement of hypoglycemic blood glucose 
showed a plasma glucose of ≤3.89 mmol/L, the CGM sys-
tem had a glucose measurement ≤4.44  mmo/L in inter-
stitial fluid. The CGM data from 1 patient in the control 
group and four miglitol-treated patients were excluded 
from the analysis due to recording failure.
Assessment of HRV was carried out using the parameters 
recommended by the working group of the European Soci-
ety of Cardiology as follows: standard deviation of normal 
RR intervals (SDNN); the root mean square of the differ-
ences in successive pairs of RR intervals (RMSSD); the ratio 
between the power of low frequency (LF) and high fre-
quency (HF) bands (LF/HF) [15]. To evaluate the measured 
values according to the time of day, the daily records were 
allocated in three time slots from 0700 to 1800 h (day-time), 
1800–0000 h (night-time) and 0000–0700 h (bed-time).
Blood sampling and analysis
Peripheral venous blood and urine samples were col-
lected from all subjects before the start of miglitol or 
control treatment. Plasma samples were collected into 
ethylenediamine tetra-acetic acid anticoagulant. Plasma 
and urinary samples were stored at −80 °C until required 
for analysis. Plasma glucose concentrations were deter-
mined by the glucose oxidase method. HbA1c was deter-
mined by high-performance liquid chromatography, and 
1,5-anhydro-d-glucitol (1,5-AG) was assayed by an enzy-
matic method. Serum total cholesterol and triglyceride 
were determined by routine enzymatic methods. High-
density lipoprotein cholesterol was measured by an enzy-
matic method after heparin and calcium precipitation.
Statistical analysis
Statistical analysis was performed using JMP software 
(version 12.2.0, SAS Institute Inc., Cary, NC, USA). 
The variables were expressed as mean ±  SD or %. Data 
between two groups were compared using the un-paired 
Student’s t test. Variables between Day 1 and Day 2 were 
compared using the paired Student’s t test for parametric 
variables or Wilcoxon signed-rank test for non-paramet-
ric variables. Data for categorical variables were analyzed 




A total of 39 participants were randomly assigned to 
either the miglitol group (n =  19) or the control group 
(n = 20). Prior to the assessment of baseline characteris-
tics, two participants were excluded due to withdrawal of 
consent. Subsequently, another two participants dropped 
out as a consequence of withdrawal of consent or refus-
ing to be tested prior to the initiation of CGM test. Sev-
enteen in the miglitol group and 18 in the control group 
were included in the full analysis (Fig. 2).
Baseline characteristics did not differ between two 
groups: the control group included 15 men and 4 women 
with a mean age of 63 ± 13 years, and the miglitol group 
included 16 men and 2 women with a mean age of 
62 ± 12 years. At baseline, body weight, body mass index, 
blood pressure, HR, and left ventricular ejection fraction 
were all comparable between the two groups (Table  1). 
Blood levels of glucose, HbA1c, 1,5-AG, lipids, and cre-
atinine were also comparable between groups. During 
CGM and Holter ECG, oral antidiabetic agents (includ-
ing metformin, gliclazide, glimepiride or pioglitazone) 
and ß-blockers (including bisoprolol and carvedilol) had 
been taken equally in the control group (15 and 55%, 
respectively) and the miglitol group (16 and 63%, respec-
tively), and these drugs were not changed during the 
study. All participants tolerated the treatment with no 
reported major adverse events.
Continuous monitoring of blood glucose
Mean variations in 24-h blood glucose levels and blood 
glucose indices measured by CGM in the control and 
miglitol groups are shown in Fig.  3. The postprandial 
peaks of blood glucose after breakfast, lunch, and supper 
were comparable between Day 1 and Day 2 in the control 
group (Fig.  3a), while they slowed after lunch and sup-
per on Day 2 as compared to Day 1 in the miglitol group 
(Fig. 3b). Results for mean glucose, minimum (min) glu-
cose, maximum (max) glucose, ∆glucose, SD glucose, 
and MAGE during 24  h were comparable between Day 
1 and Day 2 in the control group (Fig.  3c), while results 
for mean and max glucose were comparable, min glu-
cose was higher, and ∆glucose, SD glucose and MAGE 
were lower on Day 2 in the miglitol group (Fig. 3d). To see 
daily variations of blood glucose levels, we divided 24-h 
time periods into 0700–1800 h (day-time), 1800–0000 h 
(night-time), and 0000–0700  h (bed-time) (Tables  2, 3). 
In these three time periods, the control group showed 
an increase in the levels of ∆glucose during bed-time on 
Day 2. The miglitol group showed significant decreases 
in the max, ∆, and SD glucose during night-time, and an 
increase in the min glucose during bed-time. During the 
24-h CGM, hypoglycemic episodes (defined by blood glu-
cose ≤4.44  mmol/L) occurred in 35% (6/17) of patients 
(Day 1) and 35% (6/17) of patients (Day 2) in the con-
trol group (p = 0.554) (Fig. 4a, b), while the number was 
reduced from 31% (4/13) (Day 1) to 7.7% (1/13) (Day 2) 
Page 5 of 12Shimabukuro et al. Cardiovasc Diabetol  (2017) 16:86 
in the miglitol group (p = 0.089) (Fig. 4c, d). The control 
group had hypoglycemic episodes as follows: 35% (6/17) 
of patients (Day 1) and 12% (2/17) of patients (Day 2) dur-
ing day-time; 12% (2/17) (Day 1) and 18% (3/17) (Day 2) 
during night-time; and 6% (1/17) (Day 1) and 29% (5/17) 
(Day2) during bed-time. The miglitol group showed hypo-
glycemic episodes as follows: 31% (4/13) (Day 1) and 7.7% 
(1/13) (Day 2) during day-time; 7.7% (1/13) (Day 1) and 
7.7% (1/13) (Day 2) during night-time; 23% (3/13) (Day 1) 



















Fig. 2 Participants’ flow
Table 1 General characteristics of patients in the two groups
Values are mean (SD) or n (%)
LDL low-density lipoprotein, HDL high-density lipoprotein
Parameters Control (n = 19) Miglitol-treated (n = 18) P value
Men (%) 15 (79) 16 (89) 0.659
Age (years) 63 (13) 62 (12) 0.855
Body weight (kg) 69.9 (13.8) 70.9 (15.7) 0.855
Body mass index (kg/m2) 26.2 (4.7) 25.3 (4.3) 0.536
Systolic blood pressure (mmHg) 119 (20) 116 (19) 0.665
Diastolic blood pressure (mmHg) 68 (10) 67 (10) 0.866
Heart rate (beats/min) 75 (14) 76 (10) 0.794
Left ventricular ejection fraction (%) 53 (13) 54 (10) 0.760
Fasting plasma glucose (mmol/L) 7.94 (2.94) 7.83 (1.78) 0.870
HbA1c (%) 6.5 (1.1) 6.8 (0.9) 0.357
HbA1c (mmol/mol) 47.5 (11.5) 50.8 (13.7) 0.357
1,5-anhydro-d-glucitol (µg/mL) 16.0 (10.5) 12.3 (8.1) 0.240
Total cholesterol (mmol/L) 4.55 (0.93) 4.91 (1.19) 0.329
LDL cholesterol (mmol/L) 2.74 (0.75) 2.92 (0.93) 0.534
HDL cholesterol (mmol/L) 1.19 (0.34) 1.32 (0.36) 0.300
Triglyceride (mmol/L) 1.35 (0.61) 1.47 (0.98) 0.673
Non-HDL cholesterol (mmol/L) 3.36 (0.85) 3.59 (1.19) 0.528
Creatinine (µmol/L) 73.4 (17.7) 75.1 (18.6) 0.751
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Heart rate variability
Twenty-four-hour variations in HR measured by Holter 
ECG are shown in Fig. 4e (control) and Fig. 4f (miglitol-
treated). HR, SDNN, RMSSD, and LF/HF during 24-h, 
day-time, night-time, and bed-time are shown in Tables 2 
and 3. In the control group, min HR during 24-h was 
comparable between Day 1 and Day 2, but mean HR, max 
HR, SDNN, and RMSSD were increased on Day 2. Dur-
ing day-time, mean HR, min HR, max HR, SDNN, and 
RMSSD were not different between Day 1 and Day 2, 
but max HR during night-time, SDNN during night- and 
bed-time, and RMSSD during bed-time were increased, 
respectively (Table 2). On the other hand, in the miglitol 
group, mean HR, min HR, and max HR throughout the 
day were comparable on Day 1 and Day 2. In addition, 
SDNN and RMSSD were significantly increased during 
24-h (Table 3).
In the control group, mean LF/HF during 24-h was 
increased, and mean and max LF/HF during day-time 





























































































































































Fig. 3 Continuous glucose monitoring. a, b Mean variations in 24-h blood glucose measured by a continuous glucose monitoring system in 
control and miglitol groups. Lines represent mean (solid) ± SD (dotted) of blood glucose levels on Day 1 (black) and Day 2 (blue or red) in a control 
(n = 17) and b miglitol (n = 13) groups. To see daily variations of glucose levels, we divided time periods into 0700–1800 h (day-time), 1800–0000 h 
(night-time), and 0000–0700 h (bed-time). Patients took a standard regimen of breakfast, lunch, and supper. The peaks after lunch and supper on 
Day 2 in the miglitol group (red arrow, Fig. 3b) are indicated by red arrows. c, d Levels of mean glucose, minimum (min) glucose, maximum (max) 
glucose, ∆glucose, SD glucose, and MAGE during 24-h in the control and miglitol groups. Boxes represent mean ± SD, and whiskers represent min 
to max during 24-h on Day 1 and Day 2 in c control (n = 17) and d miglitol (n = 13) groups
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miglitol group, LF/HF indices during 24-h and even each 
time phase were all comparable between Day 1 and Day 
2. Both ∆glucose and SD glucose during 24-h were corre-
lated with mean LF/HF, but not with SDNN and RMSSD, 
in the miglitol group (Additional files 1, 2).
Discussion
The new findings of this pilot study are: (1) T2DM 
patients with recent ACS manifested a substantial 
number of episodes of hypoglycemia (blood glucose 
≤4.44 mmo/L) during the first 24-h CGM (Day 1). How-
ever, in the miglitol group, MAGE was significantly 
decreased on Day 2, and the min glucose level was 
increased and the episodes of hypoglycemia tended to be 
fewer after miglitol on Day 2; (2) mean and max HR dur-
ing 24-h were increased on Day 2 in the control group, 
but the increases on Day 2 were mitigated in the miglitol 
group. Simultaneously, the increase in mean LF/HF dur-
ing 24-h and day-time in the control group were also 
suppressed in the miglitol group. This is the first study 
to evaluate the associations between glucose fluctuations 
including hypoglycemia, HR and SNS activity in T2DM 
patients who had recently developed ACS. The study 
found that there is a substantial number of subclinical 
episodes of hypoglycemia in ACS and that they can be 
attenuated by diminishing the glucose fluctuations with a 
αGI, accompanied by concurrent reductions of HRV and 
autonomic nervous system activity.
There have been no published studies of 24-h con-
tinuous glucose monitoring in ACS patients. However, 
previous reports have suggested that there may be a 
substantial number of subclinical episodes of hypogly-
cemia in ACS patients. Lee et al. [6] reported that AMI 
patients had admission glucose levels <3.89  mmol/L 
in 1.20% (255/21,096) of diabetic patients and 0.73% 
(154/13,156) of non-diabetic patients. On Day 1 in the 
current study, diabetic patients with ACS had blood glu-
cose levels ≤4.44 mmol/L in 35% (6/17) of participants in 
the control group and 31% (4/13) in the miglitol group. 
Although there are several differences in the protocols 
between our study and that of Lee et  al. (admission vs 
post-admission, one-point vs continuous, and plasma 
glucose level vs interstitial blood glucose level estimated 
by CGMS), the high frequency of subclinical hypoglyce-
mia in our study is not so questionable. Hermanns et al. 
[14] reported that if the POC measurement of hypogly-
cemic plasma showed a glucose value of ≤3.89 mmol/L, 
the CGM system gave a glucose level ≤4.44  mmol/L in 
interstitial fluid. Accordingly, we adopted ≤4.44 mmol/L 
in the CGM as a hypoglycemic alert. The value for the 
Fig. 4 Impact of miglitol on glucose fluctuation, heart rate variability, and sympathetic nervous activity. a–d Plots of 24-h blood glucose meas-
ured by a continuous monitoring system in control and miglitol-treated patients. Lines indicate blood glucose levels on Day 1 and Day 2 in (a, c) 
control (n = 17) and (B, D) miglitol (n = 13) groups. To see daily variations of glucose levels, we divided time periods into 0700–1800 h (day-time), 
1800–0000 h (night-time), and 0000–0700 h (bed-time). Patients took a standard regimen of breakfast, lunch and supper. The percentage values 
indicate the proportions of patients with episodes of glucose ≤4.44 mmol/L throughout the day, indicated by blue lines on the figures. e, f Mean 
variations in 24-h heart rate (HR) in the control and miglitol groups. Lines represent mean (solid) ± SD (dotted) of mean heart rate measured by 
Holter electrocardiography on Day 1 (black) and Day 2 (blue or red) in e control (n = 18) and f miglitol (n = 17) groups. To see daily variations of 
heart rate, we divided time periods into 0700–1800 h (day-time), 1800–0000 h (night-time), and 0000–0700 h (bed-time)
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min glucose was increased and the frequency of episodes 
of blood glucose ≤4.44 mmol/L tended to be lower in the 
miglitol group on Day 2. It has been reported that αGI 
not only lowers the degree of postprandial hypergly-
cemia, but also decreases the degree of hypoglycemia, 
probably by diminishing postprandial hyperinsulinemia 
[10]. It is conceivable that αGI stabilizes glucose fluctua-
tions, thereby decreasing the frequency of hypoglycemic 
episodes.
In the control group, the average of 24-h  min HR 
was comparable between Day 1 and Day 2, but mean 
and max HR were increased on Day 2. Jabre et  al. [16] 
reported that an increase in resting HR after the onset 
of ACS was a strong predictor of cardiovascular (CV) 
mortality. Although it has been suggested that elevated 
resting HR is an intrinsic risk factor for poor outcomes 
after MI rather than merely a marker of other CV risk 
factors, the underlying mechanisms by which resting 
HR increased are unknown [16]. Although we could not 
determine the mechanism, our study has shown that 
mean and max HR were increased on Day 2 in the con-
trol group. Since the standard protocol on cardiac reha-
bilitation in Japan allows bathing and walking freely in 
the hospital 6 days after PCI [11], a day-to-day increase 
in the in-hospital activity may influence their HR on Day 
2. After being divided into three time periods, the max 
HR was increased only during night-time. The fact that 
max HR could be attenuated by miglitol suggests that HR 
may be partly affected by a postprandial or post-supper 
phase-dependent cause. Koivikko et al. [17] reported that 
marked and prolonged hypoglycemia increases the HR 
and decreases the high-frequency oscillations of HR. In 
our control group, the increases in the SNS activity dur-
ing day-time and the max HR during night-time were 
accompanied by the increases in both glucose fluctuation 
(∆glucose ranged from 1.71 to 2.20  mmo/L) and hypo-
glycemic episodes (6–29%) during bed-time on Day 2. 
While, the miglitol treatment significantly increased min 
glucose and reduced glucose fluctuations and hypogly-
cemic episodes during bed-time, accompanied by atten-
uation of both increase of mean and max HR and SNS 
activation. These results suggest that impaired hemody-
namic and neurohormonal parameters may be, in part, 
associated with the increases in both glucose fluctuation 
and hypoglycemic episodes, possibly forming a vicious 
cycle in T2DM patients with recent ACS. In addition, 
these changes may contribute to the intrinsic disturbance 
of hemodynamic and neurohormonal systems, partly 
resulting in a short-term poor prognosis after onset of 
ACS [1–6].
αGI mono- and combination therapy can delay glucose 
uptake in the intestine and lower the postprandial glu-
cose spike with infrequent development of hypoglycemia 
in patients with T2DM or impaired glucose tolerance 
[10, 18, 19]. Kitano et  al. [20] reported that short-term 
miglitol treatment in patients with postprandial hyper-
glycemia and recent ACS attenuated the postprandial 
glucose spike, accompanied by improvement of endothe-
lial function. In addition, a previous large randomized 
controlled trial and a meta-analysis showed that αGI 
treatment could prevent the development of CV events 
[21, 22]. However, the precise mechanism underlying 
αGI-induced improvement of CV outcomes is yet to be 
determined. Moreover, little is known about miglitol-
mediated effects on glucose fluctuations, HRV, and SNS 
activity in the acute phase of ACS. In the present study, 
miglitol exerted prompt beneficial effects on glucose 
fluctuations and reduced the number of hypoglycemic 
episodes. Furthermore, miglitol attenuated increases in 
the mean and max HR and the mean LF/FH throughout 
the day. Although the reason why glucose fluctuations 
parameters were not associated with time-domain HRV 
parameters remains to be explained, our results suggest 
that glucose fluctuations may be, at least partially, associ-
ated with the autonomic nerve activity. Given that oscil-
lating glucose is associated with excess oxidative stress 
in vascular endothelial cells and consequent endothelial 
dysfunction [23], it is possible that suppression of oscil-
lating glucose might contribute to CV protection after 
onset of ACS. Further studies would be required to eval-
uate possible association between glucose fluctuation and 
hemodynamics in the other classes of anti-hyperglycemic 
agents [24].
Our study has several limitations. First, although we 
detected extensive individual differences in HR and car-
diac autonomic regulation during 24 h, it was a post hoc 
exploratory analysis of a small sample of a PROBE design 
study, but not a placebo-controlled study. Because unex-
pected bias might be introduced in the assessment of 
outcome, it may be difficult to reach strong clinical con-
clusion. In addition, we could not refer to the generaliza-
tion of the current findings for other ethnicities because 
of no recruitment of the other ethnicities than Japanese, 
although previous studies demonstrated a common asso-
ciation between reduced HRV and impairment of glyce-
mic metabolisms in Hispanic/Latino and Japanese adults 
[25, 26]. Although HRV parameters are influenced by 
physical and exercise intensity, those intensity was not 
compared between the groups. In addition, although 
guidelines for clinical use of HRV recommended that 
time-domain methods should be used when using long-
term ECGs in clinical studies [27], but not frequency 
domain methods, time-domain parameters, such as 
SDNN and RMSSD, during 24-h were increased in both 
groups. Furthermore, the SDNN during night- and bed-
time increased significantly only in the control group, 
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although why such increases were less evident in the 
miglitol group remains to be clarified. In addition, sev-
eral parameters on HRV and SNS activity increased dur-
ing 24-h on Day 2 in the control group, while the time 
phases of their increases differed for HR, SDNN, and 
LH/FH, with the mean and max LF/HF increasing dur-
ing day-time, and max HR increasing during night-time. 
Therefore, further trials equipped with more appropri-
ate design and sample would be needed in the future. 
Second, the study was unable to determine if there was 
a cause-and-effect relationship. Although we obtained 
evidence that glucose fluctuations can be associated with 
changes in HR and HRV, we cannot determine whether 
glucose fluctuations, especially periods of hypoglycemia, 
can directly alter HR and HRV. We obtained no data on 
biomarkers of inflammation or oxidative stress during the 
study period. Third, because the aim of present study was 
to evaluate the effects of glucose fluctuations on HRV and 
SNS activity in T2DM patients with recent ACS, we did 
not recruit non-diabetic patients in this study. Accord-
ingly, we could not elucidate enough the specific peculi-
arities of HRV in diabetes. Accumulated evidence suggest 
that disturbed HRV was associated with metabolic syn-
drome, insulin resistance and diabetes [28, 29], and it is 
also reported that glycemic variability was independently 
associated with the presence of cardiovascular autonomic 
neuropathy in patients with uncontrolled T2DM [30]. 
Therefore, further studies are also needed to elucidate the 
diabetes-specific peculiarities of HRV and the effective 
medical care. Fourth, the study protocol focused on only 
the short-term acute-phase after ACS. Hence, we cannot 
extrapolate the miglitol-mediated beneficial effect to the 
chronic-phase. However, our study provides novel obser-
vations during the acute-phase of ACS that may partly 
contribute to future improvement of CV outcomes. Fifth, 
hyperinsulinemia and insulin resistance may be related 
to glucose fluctuation and/or incidence of hypoglycemia 
especially in diabetic patients with obesity or visceral fat 
obesity, and miglitol can diminish it [31]. Although we 
did not measure beta cell function and insulin sensitivity 
in the current study, hyperinsulinemia/insulin resistance 
and/or leptin resistance may be related to glucose fluctu-
ation and/or incidence of hypoglycemia. Sixth, the CGM 
system measured glucose levels in the interstitial fluid, 
not in plasma or in the capillary artery. Therefore, our 
data about daily glucose variations should be confirmed 
by serial measurements of plasma glucose levels.
In summary, this is the first study to evaluate the 
associations between glucose fluctuations, HRV, and 
SNS activity in T2DM patients with recent ACS. Sub-
clinical hypoglycemia was more prevalent in ACS than 
expected. Even short-term treatment of miglitol could 
alter favorably HRV, SNS activity, and glucose fluctuation 
with avoiding hypoglycemic episodes. Disturbed hemo-
dynamic and neurohormonal activities may be, in part, 
associated with increased glucose fluctuations and hypo-
glycemic episodes, suggesting a potential new strategy to 
improve outcomes in patients with recent ACS.
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